Hot Investor Mandate: Pharma/Biotech Investment Arm of Middle Eastern Family Office Invests in First-In-Class, Early-Stage Assets in Areas of Unmet Medical Need

18 Oct

A pharma/biotech investment arm of a Middle East-based family office with a total AUM of $1B through its four investment arms is actively seeking investment opportunities. The firm is stage-agnostic, however the firm is fundamentally science-driven and considers mainly early pre-clinical and clinical-stage projects, preferably with POC validation. The firm’s investment size ranges widely from $0.5M – $20M and comes in the form of straight equity. The firm seeks board representation and is a very active investor, helping guide the company’s development and strategy. The firm invests globally and may lead investments, but typically co-invests in U.S.-based companies. The firm has no targeted number of investments per year.

The firm has also recently started an accelerator program with several globally established companies for pre-seed investments in early stage assets, including tech transfer from universities. This program provides $1-1.5M in funding for two years to help companies achieve POC and be ready to raise a Series A round. The program is open to technologies developed globally that are willing to be advanced in the country the investment firm is based in.

The firm is open to both pre-clinical and clinical stage companies and is agnostic to technology type and indication. The firm has a specific interest in immuno-oncology, gene therapy and orphan or unmet medical need. The firm is only interested in first-in-class, breakthrough assets and does not consider re-purposed assets or iterative technologies. The accelerator program is focused on therapeutics in oncology, immuno-oncology, immunology, fertility, endocrinology, gene therapy, synthetic biology and microbiome-related technologies.

The firm prefers to invest early and help take the company through a major inflection point. The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: